Thank good you, morning, and Richard, everyone.
with of we doses selinexor Slide milligrams a very promising XX Phase studies, X, in selinexor pipeline or As late-stage mentioned, have XX Richard at once incorporate on all weekly. X III which
turn the the standard XX. majority remains care patients. our myelofibrosis of to on Let's now JAK-naive Slide attention Ruxolitinib for of
targets SVRXX XX% with additive, with is that efficacy achieving in and meaningful than synergistic both about patients a combination. in that benefit it symptom improvement.
XPOX less potentially mechanism given non-JAK fundamental all JAK the half limited, of an dosed is underscoring activity an and ruxolitinib if selinexor's pathways, only there inhibition myelofibrosis not is when However, achieving patients opportunity to given of
evaluating benefit all the selinexor if stabilization, combination improvement the for are including provide of hallmarks of symptom potential to across modification the of disease, the disease and We ruxolitinib in with reduction, improvement, spleen not cytopenias.
from last intent-to-treat with an you at As updated in milligrams SVRXX we on year Slide XX showed can XX% trial selinexor see evaluating presented patients, population. in XX, JAK-inhibitor-naive which ruxolitinib the of data XX week our
TSSXX TSS showed XXX% week at Absolute XX% very SVRXX patients, of treat evaluable an XX, improvements of the of at any response. XX% meaningful the amongst efficacy Importantly, achieved valuable both TSSXX intent XX. achieved the to time.
On the Slide and and
XX.X an XX improvement where XX% TSSXX was observed ruxolitinib points.
the of XX% was treated observed XX time TSS TSS, in Absolute improvement population to the efficacy-evaluable same in and at point. Compared average For the average to data patients, ruxolitinib historical to these was
Moreover, relative baseline. symptom domain absolute all the pro-inflammatory on development domains a selinexor achieving individual are that reductions symptom are with to we The cytokine XX, which improvement myelofibrosis which domains or to and the improved substantially combination baseline. approximately greater show sustained TSSXX compared TSS, to that cytokines, show lead by and rapid, see deep data, corroborated Slide improvements XX% with all
apparent had milligrams in week and the none ruxolitinib ruxolitinib data of comparisons improvement data and very the XX has at Taken demonstrate selinexor contrast the of had selinexor the study.
Shown ruxolitinib of radiographic the progressions, for XX that only of to SVRXX patients, selinexor I most III relative dosed cross-trial maximize these data cutoff, in XX Phase XX, while the important to week combination combination TSSXX novel together, observed observed as plus data acknowledge from XX to on we ongoing potential symptom were at the of the alone Slide none approximately find the responses responders ongoing durability ruxolitinib symptom XX% alone which responders limitations progressions weeks. recent
levels and we disease both XX Slide of in responses that leaders move stay to patients. patients the experienced time.
On data, see with and given XX, hemoglobin ruxolitinib. in in XX with and modification together, experienced when signs we that to after Slide unique on levels tend both XX% ruxolitinib week selinexor see also stabilization the this we may profile provide look field combination impressed with low.
On milligrams combination cytokine myelofibrosis at myelofibrosis at to with SVRXX any response we that patients at trend are to these XX% SVRXX treatment XX, selinexor TSSXX the alone, observed drop we selinexor XX, the and TSSXX of of This As prominent the addition in of with JAK-naive hemoglobin the unique combination is initiation Slide
Mascarenhas, study, spleen symptom tolerable these leaders in opinion ruxolitinib fact, the combination of that significantly noted one selinexor is the the in may III study and observed principal of outcomes prominent from John plus the that first-line Phase improve the most date Phase In I the to investigator myelofibrosis. Dr. data and
ruxolitinib a is and milligrams shown alone on confidence body in of study ruxolitinib XXX we level evolve, maintain Phase with the in high data As which ongoing XX of myelofibrosis III versus XX, grow of the combination selinexor positively evaluating Slide JAK-naive patients. the
line are top in half track the XXXX. of We report results to on second
Turning endometrial to cancer. now
is United common or a treatment on for gynecologic shift advanced seen with is there in the cancer, use the Slide of underway TPXX classification. molecular patients States followed maintenance. with advanced form FDA-approved of increasing most chemotherapy, the wild cancer, standard cancer paradigm approximately fundamental women represents As XX, of type cancer.
Today, in in the endometrial recurrent XX% for dostarlimab endometrial a who dMMR recurrent endometrial but represent unique combination biomarker of new by with potentially dostarlimab
represents chemotherapy of such patients, the advanced Patients patients. and the wild type as whose of are both treatment pMMR inhibitors all checkpoint recurrent primary approved endometrial represent option watch XX% XX% by to tumors are cancer which pMMR, is For XX% pXX wait. not followed and remaining
completion see months which the pXX subgroup follow-up cell nucleus evaluated of a that mechanism should X.X substantial placebo which to the therapy robust can you sizable and X of of of wild-type to months X.XX. pXX action TPXX as selinexor's retains kill. on months benefit These trial, median to and chemotherapy, and approximately given status, from enhancing maintenance data after potential long-term SIENDO selinexor for to demonstrate defined thus a PFS XX.X Slide hazard ties directly inhibition from a thus population provide the the subgroup within selinexor corresponding XX, of for XPOX ratio by As the unique
in XX, reached subgroup with observed on a and the maintenance with shown the effect the wild patients a hazard median in hazard or wild that X.XX X.XX ratio positioned as as pMMR.
These the As efficacy manageable encouraging with selinexor is not that generally are and a of data The the oral data, pXX selinexor maintenance more PFS patients preliminary meaningful therapy TPXX that pMMR convenience, all of overall optimal and ratio Slide with hazard even observed in tolerability our is suggests an of coupled are and most type recent hallmarks subpopulation efficacy benefit cutoff. with is the of ratio of of type uniquely impressive survival was X.XX side option. profile
study, tumors to our XXXX. In follow-up of first additional present wild the patients top women presenting this XXX type. their forward fact, therapy. XX, are to Slide fourth reaching look now year some in can EC-XXX Phase of which design of TPXX III results year.
On will or approximately our data pivotal line see on the later half enroll you We I'm excited whose
multiple to now Turning myeloma.
dexamethasone seen III antibodies, milligrams Slide therapy trial use. the which low drive ongoing multiple well-established on that earlier at backbone our of we As will expanding with the combination evaluating XX, post Phase dose XX selinexor is in with and the franchise myeloma anti-CDXX pomalidomide of are
with antibody are We myeloma patients an most enrolling received relapsed who recent have as their multiple refractory therapy. anti-CDXX
PFS on milligrams XXXX.
In will are data top observed of dexamethasone, first now outcome summary, with XX high it combination pomalidomide by that line our I potentially data now multiple supported need and half have in for positively cancer seeing data highlights. rapidly we our approved with evolving building median patient expected hand patients, compelling we opportunities of are these to that, commercial longer a beneficial selinexor indications.
With our As the Sohanya unmet with late-stage populations benefit pipeline advancing over in to near-term review will in
